Abstract: Objective：To estimate whether gonadotropin-releasing hormone (GnRH) analog administration during chemotherapy can protect premenopausal women against the ovarian toxicity. Methods：We searched the electronic bibliographic databases, including the Cochrane Library, PubMed, EMbase, CBM, CNKI, VIP database and Wanfang database to assemble relevant clinical trials. The search covered January 2000 to July 2017 and clinical studies related to GnRH analog co-treatment with chemotherapy to ovarian function in premenopausal women. Data were extracted and evaluated using the methods recommended by Cochrane handbook. The RevMan 5.3 software was used for Meta-analysis. Results：Thirteen RCTs involving 1 539 patients were included. GnRH analog co-treatment significantly increase ovarian function resumption (OR=2.42, 95%CI: 1.48~3.95, P=0.000 4). Seven trials mentioned pregnancy rates. The occurrence of spontaneous pregnancy showed statistically significant difference between GnRH analog co-treatment and the control groups (OR=1.69, 95%CI: 1.06～2.69, P=0.03). Conclusions：Evidence from RCTs suggests a potential benefit of GnRH analog co-treatment with chemotherapy in premenopausal women, with higher rates of resumption of ovarian function and improvement in pregnancy.

Key words: Neoplasms, Ovarian failure, premature, Antineoplastic combined chemotherapy protocols, Gonadotropin-releasing hormone analog